We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-7.79%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.41B
AUM Growth
-$143M
(-9.2%)
Cap. Flow
+$89M
Cap. Flow
% of AUM
6.33%
Top 10 Holdings %
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$38M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$22M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$21.2M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$18.7M |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$15.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$25.1M |
| 2 |
DexCom
DXCM
|
+$15.7M |
| 3 |
AERI
Aerie Pharmaceuticals
AERI
|
+$13.5M |
| 4 |
ASRT
Assertio
ASRT
|
+$13.4M |
| 5 |
Corbus Pharmaceuticals
CRBP
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.9% |
| 2 | Consumer Discretionary | 0.07% |
| 3 | Industrials | 0.05% |
| 4 | Energy | 0.02% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$18.3B
| $128M | 9.13% |
3,316,523
+840,251
| +34% | +$38M |
|
|
TSRO
2
DELISTED
TESARO, Inc.
TSRO
| $92.5M | 6.58% |
687,993
+5,578
| +0.8% | +$704K |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $86M | 6.11% |
17,296,672
+3,180,028
| +23% | +$22M |
|
|
4
Sarepta Therapeutics
SRPT
$1.62B
| $76M | 5.4% |
2,769,829
-625,407
| -18% | -$25.1M |
|
|
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
| $61.9M | 4.4% |
692,281
+20,833
| +3% | +$1.58M |
|
6
Travere Therapeutics
TVTX
$5.14B
| $50.9M | 3.62% |
2,687,412
+240,930
| +10% | +$4.93M |
|
|
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
| $50.5M | 3.59% |
1,927,989
+258,286
| +15% | +$6.39M |
|
8
Xencor
XNCR
$1.44B
| $47M | 3.34% |
1,785,018
+288,789
| +19% | +$6.94M |
|
|
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $45.2M | 3.22% |
3,128,978
+794,810
| +34% | +$14M |
|
|
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $39.5M | 2.81% |
498,198
-46,572
| -9% | -$3.38M |
|
|
11
Aclaris Therapeutics
ACRS
$723M
| $34.2M | 2.43% |
1,260,847
+830,847
| +193% | +$21.2M |
|
12
Ardelyx
ARDX
$1.25B
| $26.1M | 1.85% |
1,836,196
+778,939
| +74% | +$11.1M |
|
13
Iovance Biotherapeutics
IOVA
$2.04B
| $24.8M | 1.76% |
3,567,553
| – | – |
|
14
Regenxbio
RGNX
$617M
| $23.8M | 1.69% |
1,282,286
| – | – |
|
|
CLCD
15
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $23.3M | 1.66% |
641,364
+89,334
| +16% | +$3.16M |
|
|
LJPC
16
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $23.1M | 1.64% |
1,319,274
-4,050
| -0.3% | -$77.6K |
|
|
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
| $22.6M | 1.61% |
473,531
+283,531
| +149% | +$15.2M |
|
|
DBVT
18
DBV Technologies
DBVT
$805M
| $21.5M | 1.53% |
61,064
+4,737
| +8% | +$1.7M |
|
|
LKFT
19
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
| $20.6M | 1.47% |
+304,531
| New | +$18.7M |
|
|
VBIV
20
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $20.4M | 1.45% |
218,861
+116,913
| +115% | +$11.2M |
|
21
Wave Life Sciences
WVE
$1.12B
| $18.1M | 1.29% |
665,198
-18,250
| -3% | -$594K |
|
|
22
ANI Pharmaceuticals
ANIP
$1.85B
| $16.2M | 1.15% |
267,100
+255,539
| +2,210% | +$15.6M |
|
|
XLRN
23
DELISTED
Acceleron Pharma
XLRN
| $15.8M | 1.13% |
619,987
+30,097
| +5% | +$954K |
|
|
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $14.7M | 1.04% |
1,322,994
-50,290
| -4% | -$473K |
|
|
AVDL
25
DELISTED
Avadel Pharmaceuticals
AVDL
| $14.4M | 1.03% |
1,388,240
+24,529
| +2% | +$270K |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2016 Portfolio in Review
As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors deployed $89M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.
- Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
- Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
- Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
- Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
- Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.
Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.